Abstract
Objective: To explore the function of p42.3 in gastric carcinoma.
Methods: We summarized the intricate regulation of p42.3 in gastric carcinoma from several aspects, namely, the structure features, the expression level, its regulation on cell cycle and EMT, its relationship with miR-29a as well as the optimal feedback circuit involved in. Results: We addressed the complex functions of p42.3 in regulating EMT, migration, invasion, proliferation and the optimal regulation network in GC, as well as the significant up/down-stream signal molecules involved in the pathway. We have also illuminated that miR-29a can inhibit cell proliferation and block the cell cycle, at least in part, via the repression of p42.3. Conclusion: In short, p42.3 might serve as a potential therapeutic target in the treatment of GC.Keywords: p42.3, gastric carcinoma, cell cycle, EMT, miR-29a, therapeutic target.
Letters in Drug Design & Discovery
Title:p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target
Volume: 14 Issue: 10
Author(s): Hui Jing, Lu-Lu Wei, Fu-Chun Huo, Xin Ren, Jun-Nian Zheng*Dong-Sheng Pei*
Affiliation:
- Department of pathology, Xuzhou Medical University, Xuzhou 221000, China, 209 Tongshan Road, Xuzhou, Jiangsu,China
- Department of pathology, Xuzhou Medical University, Xuzhou 221000, China, 209 Tongshan Road, Xuzhou, Jiangsu,China
Keywords: p42.3, gastric carcinoma, cell cycle, EMT, miR-29a, therapeutic target.
Abstract: Objective: To explore the function of p42.3 in gastric carcinoma.
Methods: We summarized the intricate regulation of p42.3 in gastric carcinoma from several aspects, namely, the structure features, the expression level, its regulation on cell cycle and EMT, its relationship with miR-29a as well as the optimal feedback circuit involved in. Results: We addressed the complex functions of p42.3 in regulating EMT, migration, invasion, proliferation and the optimal regulation network in GC, as well as the significant up/down-stream signal molecules involved in the pathway. We have also illuminated that miR-29a can inhibit cell proliferation and block the cell cycle, at least in part, via the repression of p42.3. Conclusion: In short, p42.3 might serve as a potential therapeutic target in the treatment of GC.Export Options
About this article
Cite this article as:
Jing Hui, Wei Lu-Lu , Huo Fu-Chun, Ren Xin , Zheng Jun-Nian *, Pei Dong-Sheng*, p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target, Letters in Drug Design & Discovery 2017; 14 (10) . https://dx.doi.org/10.2174/1570180814666170306121357
DOI https://dx.doi.org/10.2174/1570180814666170306121357 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Targeting Aberrant TGF-β Signaling in Pre-Clinical Models of Cancer
Anti-Cancer Agents in Medicinal Chemistry Herpes Simplex Viruses in Antiviral Drug Discovery
Current Pharmaceutical Design One Hundred Faces of Cyclopamine
Current Pharmaceutical Design Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Current Advances in Delivery of Biotherapeutics Across the Blood-Brain Barrier
Current Drug Discovery Technologies Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Research Highlights BAY 1436032: A Novel Pan-mutant IDH1 Inhibitor Extends Survival of Mice with Experimental Brain Tumors
CNS & Neurological Disorders - Drug Targets Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation
Current Molecular Medicine Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Reactive Oxygen Species: Physiological Roles in the Regulation of Vascular Cells
Current Molecular Medicine Fluorescence Imaging of Human Cells with a Novel Conjugate of the Antifungal Nystatin
Medicinal Chemistry Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets Recent Progress in the Development of Fluorometric Chemosensors to Detect Enzymatic Activity
Current Medicinal Chemistry Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews Mode of Action of Long-Term Low-Dose Macrolide Therapy for Chronic Sinusitis in the Light of Neutrophil Recruitment
Current Drug Targets - Inflammation & Allergy Triazole and Oxadiazole Containing Natural Products: A Review
The Natural Products Journal microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design